n. Actual results (including, without limitation, the results (i) relating to the Company's commercial partnership with Endo Pharmaceuticals (including the milestone payment due upon issuance of the patent described herein), (ii) of regulatory review of BEMA Buprenorphine and the payment of related milestone payments to the Company or (iii) sales results for BEMA Buprenorphine and resulting potential royalty payments to the Company) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly
update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Readers are cautioned that peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such estimates are accurate or that such sales levels will be achieved, if at all.
Endo Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumeratPage: 1 2 3 4 5 Related biology technology :1
. BioDelivery Sciences Announces Results from Phase 3 Efficacy Study for BEMA Buprenorphine in Chronic Pain2
. BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study3
. BioCrossroads Commemorates Decade of Collaboration, Success for Indiana Life Sciences Sector4
. Spherix to Present at the LHA Life Sciences & Medical Technologies Virtual Conference on February 165
. Ambit Biosciences to Present at Two Upcoming Investor Conferences6
. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference7
. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast8
. Lend Lease Announces the Appointment of Tom Chapman as Director Operations for the Life Sciences Group in the Atlantic Region9
. Excel Life Sciences Joins DATATRAKs Connect Partner Program10
. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology11
. Elsevier Acquires QUOSA, Provider of Life Sciences Content Management and Workflow Productivity Solutions